Haleon Plc · LSE:HLN
Haleon — Q1 2025 Earnings Presentation
18 slides from Haleon's earnings presentation, April 2025
Slide 1: 2025 First quarter trading statement
2025 First quarter trading statement April 2025
Slide 2: Disclaimer
Disclaimer This presentation contains certain statements that are, or may be These forward-looking statements and views may be based on a number deemed to be, “forward-looking statements” (including for purposes of of assumptions and, by their nature, involve known and unknown risks, the safe harbor
Slide 3: Dawn Allen, CFO
Dawn Allen CFO
Slide 4: First quarter 2025 revenue
First quarter 2025 revenue £2.9bn 3.5% 2.4% /1.1% Q1 revenue Organic revenue growth1 Price / Volume Mix Q1 performance in line with expectations demonstrating Delivering on capital allocation priorities strength of the portfolio • Acquired c.£170m in shares from Pfizer as part of its Share Offering
Slide 5: Organic revenue growth momentum continues
Organic revenue growth momentum continues £m ORG1 +3.5% 2.4% (2.9)% 2,919 Organic growth1 primarily driven by pricing 1.1% Price Net M&A2 Volume/Mix (2.9)% 2,853 Net M&A dilution reflects divestment of Translational ChapStick and Nicotine Replacement Therapy business outside US foreign exchange Tran
Slide 6: Portfolio delivering robust growth
Portfolio delivering robust growth Organic • Successful innovation with Sensodyne Clinical Q1 2025 Q1 2024 revenue White and Sensodyne Clinical Repair being revenue revenue growth1 launched in a number of key markets • Strong performance in parodontax £m £m Q1 • Centrum impacted by decline in North
Slide 7: North America £980m
North America Positive volume mix performance Oral Health – Low-single digit growth impacted by timing of shipments £980m for Sensodyne. Consumption remains strong, up mid-single digits. Denture care down mid-single digit from phasing of innovation launch. Q1 2025 Revenue VMS - Double-digit digit de
Slide 8: EMEA & LATAM £1,188m
EMEA & LATAM Volume/mix impacted by weakness in Cold and Flu £1,188m Oral Health – High-single digit growth with strength across Sensodyne, parodontax and Denture Care underpinned by innovations Q1 2025 Revenue VMS – High-single digit growth. Mid-single digit growth in Centrum and strong growth acro
Slide 9: APAC £685m
APAC Broad based geographic growth with strength in India £685m Oral Health – Grew high-single digit; all three Power Brands seeing strong growth with strength in Sensodyne in India and parodontax in China Q1 2025 Revenue VMS - Mid-single digit growth with high-single digit growth in Caltrate and mi
Slide 10: Reiterating FY 2025 guidance
Reiterating FY 2025 guidance Organic revenue growth1 expected to be 4-6% Organic operating profit growth ahead of organic revenue growth1 Other modelling considerations Net Interest, Tax, and non- Net M&A and Translational 2025 phasing controlling interest Foreign Exchange • Organic revenue and orga
Slide 11: Q1 performance in line with expectations
Q1 performance in line with expectations, with +3.5% organic revenue growth1 with +2.4% price and volume/mix +1.1% Continued evolution, implementing change to become more agile Disciplined capital allocation: Completed c.£230m of £500m FY 2025 share buyback allocation and signed agreement to acquire
Slide 12: Appendix
Appendix
Slide 13: Glossary
Glossary Organic revenue growth and organic operating profit growth − Prior year and current year organic measures exclude revenue and operating profit attributable to MSAs relating to divestments and closure of production Our organic measures take our adjusted results and further exclude the impact
Slide 14: Respiratory Health
Respiratory Health Weekly US market cold and flu (million units) 25 C&F season 20 2022-23 2023-24 15 2024-25 10 5 Winter season Off season Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Source: Circana MULOC+Ecom Cough Cold Flu Sinus is aggregate of Adult CCF, Kids CCF, Adult Sinus, and Kids Sinus
Slide 15: Respiratory Health
Respiratory Health Global cold and flu portfolio weighted towards EMEA & LatAm FY24 Cold and Flu £11.2bn £1.7bn regional split Oral Health £3.3bn 29% North America 29% VMS 15% £1.7bn Cold & Flu 77% Pain Relief 23% £2.6bn EMEA & LATAM 56% Respiratory Health £1.7bn 15% Digestive Health Allergy & Other
Slide 16: Historic quarterly growth across the categories
Historic quarterly growth across the categories Organic revenue growth1 2024 2025 Q1 Q2 Q3 Q4 FY Q1 Oral Health 10.6% 9.1% 8.2% 10.6% 9.6% 6.6% VMS 9.9% 8.5% 3.7% 8.2% 7.6% 0.9% Pain Relief (4.8)% (4.0)% 3.1% 7.4% 0.1% 2.6% Respiratory Health (2.7)% (1.5)% 9.1% (1.3)% 0.9% 1.7% Digestive Health and
Slide 17: Reconciliation of Q1 organic growth
Reconciliation of Q1 organic growth Product Categories Digestive Oral Pain Respiratory Health and 2025 vs 2024 (%) Health VMS Relief Health Other Total Revenue Growth 3.0 (1.4) (0.2) (1.1) (15.7) (2.3) Organic Adjustments - - - - 16.3 2.9 Effect of Exchange Rates 3.6 2.3 2.8 2.8 2.4 2.9 Organic Reve
Slide 18: Q1 2025 Trading Statement
Q1 2025 Trading Statement Jo Russell Rakesh Patel Emma White Head of Investor Relations Director Director Joanne.c.Russell@Haleon.com Rakesh.x.Patel@Haleon.com Emma.x.White@Haleon.com +44 7787 392441 +44 7552 484646 +44 7823 523562